Zibrine

Quick links to important sections

Zibrine

Method of action: Psychoanaleptics

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zibrine

What is Zibrine? Identity and Classification

Property Description
Active ingredient Hypericum perforatum Dry Extract (Standardized to Hyperforin/Hypericin)
Form Oral Solid Forms (Capsules, Tablets)
Pharmacological class Herbal Antidepressant / Anxiolytic
Common use Relief of mild mood disturbances and nervous states
Origin Natural (Phytopharmaceutical)

Zibrine is formally identified as a phytopharmaceutical—a medicinal product derived from a plant source—specifically a standardized dry extract obtained from the aerial parts of Hypericum perforatum L., commonly known as St. John's wort. This classification establishes its natural origin and places it within the high-level pharmacological class of Herbal Antidepressants and Anxiolytics. Zibrine is typically presented as an oral solid form for systemic use.

Pharmacological evidence supports the extract's use, confirming its recognition for therapeutic action against symptoms of mild mental stress and exhaustion. As a standardized extract, Zibrine offers a distinct profile from non-standardized herbal supplements by ensuring a consistent concentration of active plant components, thus meeting the quality requirements for a medicinal product.

Composition and The Core Active Ingredient

The composition of Zibrine is defined by its primary active ingredient, which is the standardized dry extract of Hypericum perforatum. This extract contains a complex matrix of phytochemicals, with the most critical constituents being the lipophilic phloroglucinol Hyperforin and the naphthodianthrone Hypericin.

The overall therapeutic profile of the drug is fundamentally linked to the synergistic effect of these components. Research indicates that the key components of the extract are effective in supporting and stabilizing mood for those experiencing mild-to-moderate depressive states. The Zibrine formulation functions as a monotherapy, delivering a fixed, multi-component botanical preparation rather than a single isolated chemical.

What is the General Purpose of Zibrine?

The general purpose of Zibrine is to provide support for emotional well-being by facilitating a calming effect and promoting a balancing effect on the nervous system. The drug aids in the relief of symptoms associated with mild to moderate depressive episodes and various psycho-vegetative disorders, such as feelings of persistent nervosity or emotional restlessness. A typical use scenario involves the patient seeking to stabilize daily emotional fluctuations stemming from stress. By influencing neurochemical signaling, Zibrine’s overall function is to help support the patient's mood and general disposition.

Regulatory References

  1. National Center for Biotechnology Information

What side effects are possible with Zibrine?

Possible Side Effects and Safety Information

The official safety profile for Zibrine (Hypericum perforatum dry extract) outlines adverse reactions grouped by affected physiological systems and defines specific constraints, strictly based on regulatory documents.

Adverse Reaction Categories

Side effects documented in regulatory labeling are categorized by the system they affect. These commonly include Gastrointestinal Disorders (such as dry mouth and general disturbances), Skin and Subcutaneous Tissue Disorders (including allergic skin reactions), and Nervous System effects (such as dizziness, fatigue, restlessness, and sleep problems). For many of these effects, regulatory sources specify that the frequency of occurrence is not known, meaning an accurate estimate cannot be determined from available data.

Serious Safety Concerns

The most significant safety concerns documented in official labeling relate to light exposure and pharmacological interactions.

Safety Concern Official Description
Photosensitivity Fair-skinned individuals are at risk of intensified sunburn-like reactions when exposed to intense UV light or sunlight during treatment.
Drug Interactions Concomitant use with certain prescription medicines may result in reduced therapeutic efficacy (e.g., specific immunosuppressants, anticoagulants, or oral contraceptives) or may increase the risk of serious serotonin-related effects (e.g., when combined with certain antidepressants).

Population-Specific Restrictions

Official regulatory bodies do not recommend the use of Zibrine during pregnancy or lactation due to a lack of sufficient clinical safety data. The specific sensitivity of fair-skinned individuals to UV light also constitutes a population-specific safety consideration.

General Safety Limitations

During the entire course of treatment, intense exposure of the skin to UV light (such as sunbathing or sunbeds) must be avoided to mitigate the documented risk of photosensitivity.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information is based strictly on official data from governmental regulatory documents regarding overdose with Zibrine (Standardized Hypericum perforatum extract).

Documented Overdose Manifestations

In cases of massive overdose, the official regulatory information indicates an intensification of certain effects. Documented presentations include neurological disturbances such as confusion, delirium, manic attack, and convulsions (seizures). Systemic effects such as hypertension (high blood pressure) and tachycardia (rapid heart rate) are also reported.

Overdose also significantly increases the risk of photosensitivity. If severe, this may lead to severe sunburn, blistering, or skin rash after exposure to intense UV light (sunlight or tanning beds).

Severe Outcomes Documented
Serotonin Syndrome: A severe, potentially life-threatening complication characterized by high fever, severe tremor, and irregular heartbeat.
Severe Phototoxicity: Acute, severe skin reactions requiring immediate attention after UV light exposure.

Immediate Actions Required

If a massive overdose is suspected, or if severe symptoms develop, individuals must seek immediate medical attention. The official required management is centered on the institution of appropriate symptomatic and supportive care.

It is officially noted that no specific antidote is documented for Hypericum perforatum overdose. Therefore, treatment focuses on relieving symptoms and preventing complications. A key procedural step required is the avoidance of intense UV-exposure for a period following the overdose to mitigate the risk of severe skin reactions.

Therapeutic Uses of Zibrine

What Zibrine Treats: Main Uses and Benefits

The therapeutic application of Zibrine (standardized Hypericum perforatum extract) centers on providing supportive symptom management for emotional well-being and associated nervous conditions, generally applied across the spectrum of mild-to-moderate symptom severity. The extract's relevance in this therapeutic domain includes its application for symptoms of mild or moderate depression.

Zibrine is commonly used to help manage symptoms related to low mood, sadness, emotional dullness, emotional restlessness, and persistent nervosity, which are core manifestations of mild to moderate depressive episodes and associated stress-related disturbances.

“The primary goal is to provide supportive relief that helps patients cope more steadily with symptom fluctuations during periods of emotional tension.”

This support contributes to easing the overall symptom load and assists with maintaining functional stability by providing supportive relief when these symptoms interfere with routine activities. Zibrine is applied in addressing functional symptom clusters that often accompany these disturbances, such as related sleep disturbances and feelings of stress-induced fatigue.

Quick Fact: Support for Low Mood and Nervous Tension Symptoms
Zibrine is considered relevant for easing challenging manifestations that create noticeable functional strain in conditions characterized by periods of heightened symptoms.

Regulatory References

  1. National Institutes of Health (NIH) overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Zibrine? Official Regulatory Information

The eligibility for Zibrine (Hypericum perforatum extract) is strictly defined by regulatory authorities and is generally restricted to adults (18 years and older) for the relief of mild mood disturbances.

Contraindicated Populations

Use of Zibrine is contraindicated (must not be used) in several population groups, primarily due to significant interaction risks and clinical status. Individuals with known hypersensitivity to the active substance, as well as those with severe depression, are ineligible. Absolute prohibitions also apply to patients concurrently taking critical medications, including immunosuppressants (e.g., Ciclosporin), oral anticoagulants (e.g., Warfarin), HIV protease inhibitors, and hormonal contraceptives, as these co-treatments may lead to reduced efficacy of those essential medicines. Concurrent use with certain other antidepressants and Triptans is also contraindicated.

Restricted and Non-Recommended Use

Zibrine is not recommended for use in children and adolescents under 18 years of age because sufficient safety and efficacy data are lacking for this age group. Use is also not recommended during pregnancy or lactation due to insufficient data or potential for compound transfer. Patients using Zibrine must also avoid intense UV exposure due to the risk of photosensitivity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Zibrine outlines several categories of drug-drug and drug-product interactions that can significantly alter the exposure of Zibrine or co-administered medications.


Exposure-Modifying Interactions

Zibrine is a substrate of the Cytochrome P450 (CYP) 3A4 enzyme and is also a documented moderate CYP3A4 inducer. Consequently, co-administration with strong CYP3A inducers (e.g., rifampicin, St. John’s Wort) is contraindicated, as they can severely reduce Zibrine concentrations and efficacy. Conversely, strong CYP3A inhibitors (e.g., ketoconazole) significantly increase Zibrine exposure, often necessitating a Zibrine dose adjustment.

Transporter and Pharmacodynamic Interactions

Zibrine is an officially documented inhibitor of drug transporters, including OATP1B1/1B3 and P-glycoprotein (P-gp), leading to increased systemic levels of sensitive transporter substrates (e.g., statins, digoxin). Furthermore, concurrent use with other CNS depressants or alcohol is restricted due to the risk of additive pharmacodynamic effects, such as enhanced sedation. Due to additive risk, caution is advised with other medications known to prolong the QT interval.

Specific Restrictions

Substance Category Interaction Constraint
Strong CYP3A Inducers Contraindicated
Alcohol Restricted use due to additive CNS effects
Antacids (Polyvalent Cations) May require a minimum 2-hour dosing separation

Specific precautions are noted for patients with severe renal impairment where concurrent use with CYP3A inhibitors may pose an increased risk of Zibrine accumulation.

Mechanism of Action

The mechanism of Zibrine involves its complex, multi-component action on the central nervous system ( CNS) at the molecular and cellular levels, strictly modulating key physiological processes associated with neurotransmitter signaling and neuronal activity.


Multi-Target Neurotransmitter Transport Modulation

Zibrine acts primarily through its constituent Hyperforin to non-competitively inhibit the reuptake of multiple neurotransmitters, including Serotonin ( 5-HT), Norepinephrine ( NE), Dopamine ( DA), GABA, and Glutamate. This broad-spectrum interference with the transport system elevates the effective concentration of these key signaling molecules, initiating a cascade resulting in altered receptor signaling.


Sustained CNS Pathway Stabilization

The molecular action of multi-target reuptake inhibition leads to sustained changes in neurotransmitter levels, which drives a long-term adaptive response in the postsynaptic receptors. This mechanism helps to normalize neuronal signaling kinetics, assisting in the establishment of a stabilized state of neuronal signaling within the CNS pathways.


Support for Neuronal Resilience and Protection

Beyond neurotransmitter modulation, the extract's Flavonoids and other components contribute a crucial secondary mechanism involving antioxidant activity and the modulation of neuroinflammatory processes. This action provides cellular defense against oxidative stress, thereby modulating its impact on neuronal activity.

Dosage and Administration Information

Zibrine is intended for oral administration. The medicine is supplied as an oral solid form, such as a tablet or capsule, which must be swallowed whole with water and should not be crushed or chewed; this is necessary to maintain the integrity of the standardized extract's release profile.

Standard Dosing and Frequency

The typical dosing regimen described for adults involves a daily intake ranging from 600 mg to 900 mg of the standardized extract. This daily quantity is most commonly administered in divided doses, such as 300 mg taken twice daily, to achieve a stable systemic exposure. A consistent dosing schedule is often established, with doses taken at the same time each day, potentially after meals, as part of the procedure for proper use.

Course Duration and Procedural Rules

The duration of use is defined by a specific response window. The extract is typically continued for a minimum of four weeks before determining the extent of its functional effect. If a dose is missed, the schedule should be resumed with the next planned dose without attempting to double the amount. Usage is generally not recommended for children and adolescents under 18 years due to a lack of sufficient clinical safety and efficacy data for this population.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zibrine

Evidence for use in Mild to Moderate Depressive Episodes

The majority of the formal research on Zibrine (standardized Hypericum perforatum extract) involves numerous clinical trials and systematic reviews published in peer-reviewed scientific literature. Research was studied for this extract primarily in conditions characterized by fluctuating or episodic manifestations of mild to moderate severity. These studies are often designed as short-term Randomized Controlled Trials (RCTs), comparing the extract against an inactive placebo or, in some cases, standard antidepressant medications. Researchers monitored outcomes related to symptom intensity or variability using established clinical scales.

Studies conducted during periods of increased symptom activity have explored how symptoms evolved in the observed populations over acute treatment phases, typically lasting 6 to 12 weeks. Findings from systematic reviews indicate patterns observed in the studies where studies monitored whether measurements of symptom severity changed differently compared to placebo groups. This research contributes to understanding symptom patterns within the scope of mild-to-moderate conditions.

Evidence for the Relief of Nervous States and Restlessness

Research exploring short-term symptom changes was also evaluated for symptoms associated with nervous states, often experienced alongside mild low mood. These studies have examined outcomes related to systemic or functional imbalance, such as feelings of restlessness or generalized anxiety, which are often tracked as secondary endpoints within the main mood trials. Findings indicate patterns related to these secondary outcomes, and the research highlights changes measured during the acute treatment phase.

Scientific Uncertainty and Research Gaps

The available evidence is largely confined to the specific populations studied (adults with mild-to-moderate intensity symptoms). Research remains limited for certain groups where data are still emerging or insufficient, such as in cases of severe depressive episodes or in pediatric populations, meaning subgroup findings are uncertain. Additionally, the evidence base is primarily focused on short follow-up durations, and long-term effects are not fully established.

Key Studies & References

  1. NIH National Center for Complementary and Integrative Health (NCCIH) Overview of St. John's Wort

Frequently Asked Questions (FAQ)

Common questions about Zibrine (FAQ)


Q: How quickly does Zibrine start to work?

Official regulatory documents indicate that Zibrine requires a period of consistent use before its effects can be evaluated. The full functional effect of the medicine should be determined only after an individual has been taking it for a minimum of four weeks, which suggests a gradual onset of action.


Q: What is the typical time frame to see the expected effects of Zibrine?

Regulatory instructions specify that the treatment requires a response window of at least four weeks. This minimum duration is set to allow time for the standardized extract to achieve a stable systemic exposure necessary for its intended functional effect.


Q: What happens if I miss a day of Zibrine?

If a dose is missed, regulatory guidance instructs users to resume their regular schedule with the next planned dose. Regulatory guidance describes that users should not double the amount of Zibrine taken to compensate for the missed day.


Q: What happens if I accidentally skip several doses of Zibrine?

Official product information emphasizes that consistent intake is important for Zibrine's intended effects. Official information describes that interruptions to the treatment schedule should be avoided, and such occurrences are generally reviewed with a healthcare professional.


Q: Is it okay if I stop taking Zibrine once I feel better?

Official instructions describe that the process of stopping Zibrine should be discussed with a healthcare provider. Regulatory sources describe that discontinuation is a process that is typically managed by a healthcare professional, as stopping the medicine abruptly may be associated with changes in well-being.


Q: What is the risk of stopping Zibrine suddenly?

The official prescribing information indicates that consultation with a healthcare professional is generally sought for any decision to stop Zibrine. This is because sudden discontinuation may be associated with certain effects, and a proper procedure should be followed for managing treatment completion.


Q: Is Zibrine a long-term medication?

Regulatory documentation defines a recommended maximum duration for the use of Zibrine. Official documentation specifies recommended course durations, and continuation beyond that period is generally subject to professional review.


Q: Do you have to take Zibrine forever?

The official documentation describes that the duration of treatment is typically variable and defined by a necessary response window, rather than indefinite use. The medicine is described by specific periods of use based on a necessary response window.


Q: Can Zibrine affect my sleep?

Yes, official reports of possible side effects include sleep-related issues. Insomnia (difficulty sleeping) and vivid dreams are described in regulatory documents as effects that have been reported with Zibrine use.


Q: Are headaches a common side effect of Zibrine?

According to official documentation, headache is listed as a common adverse reaction associated with Zibrine. This type of reaction is frequently observed in clinical reporting.


Q: Can Zibrine cause weight gain?

Official product information describes that changes in weight have been reported as adverse events with Zibrine use. Both increases and decreases in weight are included among the observations noted in regulatory documents.


Q: What are the most commonly reported side effects of Zibrine?

Based on official documents, the most frequently observed adverse reactions include headache, fatigue, and general gastrointestinal discomfort, such as nausea or stomach upset.


Q: Does Zibrine interact with alcohol?

Regulatory guidance describes that consumption of alcohol is generally avoided during treatment with Zibrine. This is due to the possibility that alcohol may amplify the effects Zibrine has on the central nervous system (CNS).


Q: Can I take Zibrine with my vitamins or supplements?

Official regulatory information describes a potential for interaction with certain supplements, particularly those that affect the liver enzyme CYP3A4. Official documents describe that the concurrent use of supplements is generally reviewed with a healthcare professional.


Q: Is it safe to take Zibrine with common over-the-counter pain relievers?

Official documents describe that certain non-steroidal anti-inflammatory drugs (NSAIDs) may have a potential for interaction with Zibrine. Official sources describe that the use of over-the-counter pain relievers with Zibrine is typically reviewed by a prescribing professional.


Q: Does Zibrine interact with birth control pills?

Yes, official regulatory information specifically states that Zibrine may reduce the effectiveness of hormonal contraceptives, such as birth control pills. This is due to Zibrine's influence on specific liver enzymes responsible for processing the hormones.


Q: Can I use Zibrine if I am elderly?

The official labeling contains a section on Geriatric Use. This section describes that no overall differences in safety or effectiveness were observed between elderly subjects and younger subjects in the clinical trials, though use in this population is generally reviewed with a healthcare professional.


Q: Why is Zibrine not recommended for people with [Specific Organ] issues?

Regulatory contraindications specifically state that Zibrine is not recommended for individuals with severe impairment of kidney function. Contraindications are conditions where the medicine must not be used because the harm outweighs the potential benefit.


Q: Is Zibrine safe to use during pregnancy?

Official regulatory documents indicate that there are no adequate and well-controlled studies of Zibrine use in pregnant women. Use during pregnancy is described as generally not recommended, except in situations where professional guidance has weighed the potential benefit against the potential risk.


Q: Can I use Zibrine while breastfeeding?

No, official information describes that components of Zibrine may be excreted in human milk. For this reason, Zibrine is not generally recommended for use by individuals who are breastfeeding.


Q: Where does Zibrine come from (meaning, what kind of drug is it)?

Zibrine is officially defined in regulatory documentation as a standardized extract of the plant Hypericum perforatum (St. John's Wort). This means it contains specific, measured levels of the plant's active components.


Q: Are there any serious warning signs I should look for when taking Zibrine?

Regulatory documentation lists serious warnings, including the potential for severe skin reactions and increased sensitivity to sunlight. Official documents describe these signs as important and advise that they warrant prompt attention from a medical professional.


Q: What does 'contraindication' mean when it talks about Zibrine?

In official drug information, a contraindication refers to a specific condition or circumstance where the medicine must not be used. It signifies that using Zibrine under that condition could pose an unacceptable risk where the harm significantly outweighs the benefit.


Q: What kind of research has been done on Zibrine?

Official regulatory documents summarize the clinical studies that have examined Zibrine's uses. These studies have primarily focused on its use in the treatment of mild-to-moderate mood issues to support its approved status.


Q: What is the evidence for Zibrine's uses?

The evidence base for Zibrine is detailed in the Clinical Studies section of the official label. This section describes the outcomes of clinical trials that support the medicine's approved uses.


Q: Can Zibrine make me feel tired or drowsy?

Yes, regulatory documentation describes that Zibrine may cause fatigue or somnolence (drowsiness). Official sources indicate that this effect could influence the ability to drive or safely operate machinery.


Q: Is it normal to feel [minor, non-serious symptom] when starting Zibrine?

The official product documentation categorizes certain minor effects, such as transient stomach upset, as 'very common.' This means they are frequently observed in patients when starting treatment and are generally expected.


Q: Does Zibrine affect mood or personality?

Regulatory documents list 'psychiatric disorders' as a system organ class where adverse reactions have been reported. These reactions include feelings like nervousness and restlessness.


Q: What happens if I take too much Zibrine?

The Overdosage section in official labeling describes the expected symptoms following an overdose, which may include nausea and dizziness. The documentation describes that contacting emergency services is warranted in the event of an accidental overdose.


Q: Is Zibrine habit-forming or addictive?

Official regulatory documents do not describe Zibrine as having potential for abuse or dependency. Furthermore, it is not classified as a controlled substance under federal scheduling.


Q: Do I need to change my diet while taking Zibrine?

While the official documentation does not mandate broad dietary changes, it specifies that certain food-drug interactions can occur. The primary focus is on avoiding specific foods that may interact with Zibrine.


Q: Is there a food I should avoid when taking Zibrine?

Yes, official regulatory sources note a potential interaction with foods containing high levels of Tyramine. You are advised that these foods are generally avoided due to the risk of an adverse hypertensive reaction.


Q: Does Zibrine require any special monitoring or blood tests?

Regulatory documents indicate that no routine laboratory testing or specific blood tests are generally required for monitoring the use of Zibrine. Any individualized monitoring instructions are typically managed by a healthcare provider.


Q: Does Zibrine cause stomach problems?

Yes, gastrointestinal disorders are listed in regulatory sources as very common or common side effects. These problems may include discomfort, nausea, vomiting, or diarrhea.


Q: What are some documented food-drug interactions for Zibrine?

Official documents describe interactions with tyramine-rich foods, which could potentially lead to certain adverse effects. A complete list of known interactions is generally available through a healthcare professional.


Q: Is Zibrine a Schedule drug?

Official regulatory classifications confirm that Zibrine is not listed as a controlled substance under federal scheduling. This means it is not designated by the government as having a potential for abuse or dependency.


Q: What is the half-life of Zibrine?

Pharmacokinetic data in regulatory documents indicates that the half-life of Zibrine's primary active component, Hyperforin, is approximately 12 hours. This time frame describes how long it takes for the concentration of the substance in the body to be reduced by half.

How should Zibrine be stored and disposed of?

How to Store and Dispose of Zibrine

Zibrine (standardized Hypericum perforatum extract) must be stored and handled according to specific regulatory requirements to maintain product stability and ensure safety.

Storage Requirements

Condition Requirement Restriction
Temperature Store below 25 C (or at controlled room temperature). Do not use after the labeled expiry date.
Protection Protect from both light and moisture. Store only in the original package.
Safety Keep the medicine out of the sight and reach of children. Must be stored in a tightly closed container.

Disposal Instructions

Unused or expired Zibrine must not be disposed of via household waste or flushed down the toilet, as this protects the environment. Patients must consult their pharmacist or a local official drug take-back program for instructions on the correct disposal of the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zibrine found in:

A-Z Index: